134 related articles for article (PubMed ID: 37706450)
1. Rational Design of Sulfonyl-γ-AApeptides as Highly Potent HIV-1 Fusion Inhibitors with Broad-Spectrum Activity.
Xue S; Xu W; Wang L; Xu L; Calcul L; Teng P; Lu L; Jiang S; Cai J
J Med Chem; 2023 Sep; 66(18):13319-13331. PubMed ID: 37706450
[TBL] [Abstract][Full Text] [Related]
2. Helical sulfonyl-γ-AApeptides for the inhibition of HIV-1 fusion and HIF-1α signaling.
Zhao X; Liu H; Zhang JC; Cai J
RSC Med Chem; 2024 May; 15(5):1418-1423. PubMed ID: 38784464
[TBL] [Abstract][Full Text] [Related]
3. γ-AApeptides: Design, Structure, and Applications.
Shi Y; Teng P; Sang P; She F; Wei L; Cai J
Acc Chem Res; 2016 Mar; 49(3):428-41. PubMed ID: 26900964
[TBL] [Abstract][Full Text] [Related]
4. An HR2-Mimicking Sulfonyl-γ-AApeptide Is a Potent Pan-coronavirus Fusion Inhibitor with Strong Blood-Brain Barrier Permeability, Long Half-Life, and Promising Oral Bioavailability.
Xue S; Xu W; Wang L; Wang X; Duan Q; Calcul L; Wang S; Liu W; Sun X; Lu L; Jiang S; Cai J
ACS Cent Sci; 2023 May; 9(5):1046-1058. PubMed ID: 37252367
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Hypoxia-Inducible Transcription Factor (HIF-1α) Signaling with Sulfonyl-γ-AApeptide Helices.
Jiang W; Abdulkadir S; Zhao X; Sang P; Tomatsidou A; Zhang X; Chen Y; Calcul L; Sun X; Cheng F; Hu Y; Cai J
J Am Chem Soc; 2023 Sep; 145(36):20009-20020. PubMed ID: 37665648
[TBL] [Abstract][Full Text] [Related]
6. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
[TBL] [Abstract][Full Text] [Related]
7. Peptide and non-peptide HIV fusion inhibitors.
Jiang S; Zhao Q; Debnath AK
Curr Pharm Des; 2002; 8(8):563-80. PubMed ID: 11945159
[TBL] [Abstract][Full Text] [Related]
8. γ-AApeptides as a New Class of Peptidomimetics: Design, Synthesis, and Applications.
Su M; Zhu Y; Wang W; Liu F; Li H
Curr Top Med Chem; 2021; 21(28):2574-2592. PubMed ID: 34315367
[TBL] [Abstract][Full Text] [Related]
9. The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors.
Zhu Y; Ding X; Yu D; Chong H; He Y
J Virol; 2019 Dec; 94(1):. PubMed ID: 31619552
[TBL] [Abstract][Full Text] [Related]
10. γ-AApeptides as a New Strategy for Therapeutic Development.
Nimmagadda A; Shi Y; Cai J
Curr Med Chem; 2019; 26(13):2313-2329. PubMed ID: 29110596
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of β-catenin/B cell lymphoma 9 protein-protein interaction using α-helix-mimicking sulfono-γ-AApeptide inhibitors.
Sang P; Zhang M; Shi Y; Li C; Abdulkadir S; Li Q; Ji H; Cai J
Proc Natl Acad Sci U S A; 2019 May; 116(22):10757-10762. PubMed ID: 31088961
[TBL] [Abstract][Full Text] [Related]
12. Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors.
He Y; Cheng J; Li J; Qi Z; Lu H; Dong M; Jiang S; Dai Q
J Virol; 2008 Jul; 82(13):6349-58. PubMed ID: 18417584
[TBL] [Abstract][Full Text] [Related]
13. A novel HIV-1 gp41 tripartite model for rational design of HIV-1 fusion inhibitors with improved antiviral activity.
Su S; Wang Q; Xu W; Yu F; Hua C; Zhu Y; Jiang S; Lu L
AIDS; 2017 Apr; 31(7):885-894. PubMed ID: 28121713
[TBL] [Abstract][Full Text] [Related]
14. ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer.
Yu F; Lu L; Liu Q; Yu X; Wang L; He E; Zou P; Du L; Sanders RW; Liu S; Jiang S
Biochim Biophys Acta; 2014 May; 1838(5):1296-305. PubMed ID: 24388952
[TBL] [Abstract][Full Text] [Related]
15. Sulfono-γ-AApeptides as Protein Helical Domain Mimetics to Manipulate the Angiogenesis.
Xue S; Wang L; Cai J
Chembiochem; 2022 Nov; 23(22):e202200298. PubMed ID: 36006398
[TBL] [Abstract][Full Text] [Related]
16. α-Helix-Mimicking Sulfono-γ-AApeptide Inhibitors for p53-MDM2/MDMX Protein-Protein Interactions.
Sang P; Shi Y; Lu J; Chen L; Yang L; Borcherds W; Abdulkadir S; Li Q; Daughdrill G; Chen J; Cai J
J Med Chem; 2020 Feb; 63(3):975-986. PubMed ID: 31971801
[TBL] [Abstract][Full Text] [Related]
17. Molecular dynamics studies of the inhibitor C34 binding to the wild-type and mutant HIV-1 gp41: inhibitory and drug resistant mechanism.
Ma X; Tan J; Su M; Li C; Zhang X; Wang C
PLoS One; 2014; 9(11):e111923. PubMed ID: 25393106
[TBL] [Abstract][Full Text] [Related]
18. Sulfonyl γ-AApeptide tools for modulating biology.
Fontaine J; Cai J
Methods Enzymol; 2024; 698():247-262. PubMed ID: 38886034
[TBL] [Abstract][Full Text] [Related]
19. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Xiong S; Borrego P; Ding X; Zhu Y; Martins A; Chong H; Taveira N; He Y
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795437
[TBL] [Abstract][Full Text] [Related]
20. Hydrophobic mutations in buried polar residues enhance HIV-1 gp41 N-terminal heptad repeat-C-terminal heptad repeat interactions and C-peptides' anti-HIV activity.
Zheng B; Wang K; Lu L; Yu F; Cheng M; Jiang S; Liu K; Cai L
AIDS; 2014 Jun; 28(9):1251-60. PubMed ID: 24625369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
